Nektar Therapeutics (NKTR) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $70.65 --0%
Revenue Growth %: -11.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: -11.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $21.79 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue
- Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
